Brief Glance provided the most data-rich coverage, citing specific clinical performance metrics from the CLiMB study that demonstrate HelioLiver's superiority over current screening methods.
Brief Glance reports that HelioLiver achieved 76% sensitivity for early-stage liver cancer in the CLiMB clinical trial — substantially exceeding ultrasound's 47% sensitivity. The article notes HelioLiver identified 28.6% of tumors under 2cm while ultrasound detected none at that size. With liver cancer five-year survival at 70% when detected early, the Quest partnership across nearly 7,700 locations addresses the screening gap where 80–90% of eligible patients skip recommended biannual ultrasounds.